

## **Zydus receives final approval from the USFDA for Budesonide Capsules**

---

*Ahmedabad, India, 5 May 2017*

Zydus Cadila has received the final approval from the USFDA to market Budesonide Capsules, 3 mg (Enteric Coated). The drug is a corticosteroid used for its anti-inflammatory action.

It will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Budesonide is \$ 285.8 million (*IMS MAT March 2017*).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*